Ranolazine is an antianginal medication. On January 31, 2006, ranolazine was approved for use in the United States by the FDA for the treatment of chronic angina.
Ranolazine
| Description | |
|---|---|
| (RS)-N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)-propyl]piperazin-1-yl]acetamide | |
| 142387-99-3 | |
| C24H33N3O4 | |
| RANOLAZINE;n-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide;1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethy]piperazine;CVT 303;Ranexa;Renexa;RS 43285-003;1-Piperazineacetamide,N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]- | |
| For the treatment of chronic angina. It should be used in combination with amlodipine, beta-blockers or nitrates. | |
Copyright © 2014. All Rights Reserved at Jai Radhe Sales.
Powered by: Adit Microsys
